News Search Results
Apr 16, 2025, 21:00 ET LG CNS Brings Smart City Innovation to Hogansville, Georgia
2025 /PRNewswire/ -- LG CNS, a leading AX (AI Transformation) company in Korea, signed its first official contract with a U.S. government agency to build smart city infrastructure in Hogansville, Georgia. This agreement calls for LG CNS to install smart poles and an
More news about: LG CNS
Apr 16, 2025, 16:19 ET COHEN & STEERS REPORTS RESULTS FOR FIRST QUARTER 2025
YORK, April 16, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended March 31, 2025. The earnings release along with the accompanying earnings
More news about: Cohen & Steers, Inc.
Apr 16, 2025, 09:00 ET NEURELIS ANNOUNCES FDA APPROVAL FOR IMMEDIATE USE SEIZURE MEDICATION VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5
Hypersensitivity to diazepamAcute narrow-angle glaucomaCentral Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness,
More news about: Neurelis, Inc.
Apr 15, 2025, 09:10 ET XellSmart's Allogeneic iPSC-derived Cell Therapies for Parkinson's Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials
therapy for ALS. These milestones position XellSmart as a global leader in advancing innovative iPSC-derived regenerative cell therapies for CNS diseases, including Parkinson's disease and ALS. Dr. Michael Lee (Xiang
More news about: XellSmart
Apr 15, 2025, 09:00 ET NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced positive results from Study KO-943, a preclinical investigation evaluating the efficacy of Mazindol in mitigating fentanyl-induced
More news about: NLS Pharmaceutics Ltd.
Apr 14, 2025, 13:53 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP
Apr 14, 2025, 08:38 ET Mobile Communications America, Inc. Honored by Ericsson as Acceleration Partner of the Year
demonstrated a significant investment in understanding and promoting our ever-expanding portfolio of connectivity solutions." To learn more about MCA's CNS Solutions, please visit
More news about: MCA
Apr 14, 2025, 07:00 ET hyperCORE Welcomes Atlas Clinical Research, Strengthening North American Partner Site Network
physicians form a bridge from patients and their families to new treatments that could improve their lives. Atlas specializes in infectious disease, CNS, gastroenterology, cardiovascular, metabolic, and general medicine and plans to expand across the United States to reach
More news about: hyperCORE International
Apr 10, 2025, 09:00 ET Prolerity Clinical Research Announces Stacey (Colado) Johnson as Chief Operating Officer
Prolerity is a research site network with therapeutic coverage across complex and challenging Phase I–III trials, including gastroenterology, cardiology, CNS, and metabolic diseases. Prolerity owns and operates New Orleans–based
More news about: Prolerity Clinical Research
Apr 10, 2025, 07:00 ET NorthC Data Centers Doubles Down on Corero Network Security for European Expansion
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced the renewal of its strategic partnership with NorthC Data
More news about: Corero Network Security
Apr 09, 2025, 17:30 ET Cohen & Steers, Inc. to Release First Quarter 2025 Results on April 16, 2025
YORK, April 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release first quarter 2025 results after the market closes on Wednesday, April 16, 2025.
More news about: Cohen & Steers, Inc.
Apr 09, 2025, 08:00 ET Ractigen's RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances
development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics.
More news about: Ractigen Therapeutics
Apr 08, 2025, 17:45 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for March 2025
YORK, April 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $87.6 billion as of March 31, 2025,
More news about: Cohen & Steers, Inc.
Apr 08, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP
Apr 07, 2025, 09:00 ET NEURELIS WILL HIGHLIGHT ANALYSES OF SEIZURE TREATMENT WITH DIAZEPAM NASAL SPRAY AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
Hypersensitivity to diazepamAcute narrow-angle glaucomaCentral Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Apr 04, 2025, 16:05 ET China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product
More news about: China Pharma Holdings, Inc.
Apr 04, 2025, 09:05 ET SK Life Science, Inc. to Showcase Important XCOPRI® (cenobamate tablets) CV Data on Responsive Neurostimulation Epileptiform Events at the 77th American Academy of Neurology (AAN) Annual Meeting
SK Life Science, Inc., a global leader in developing treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., will present meaningful encore data on XCOPRI® (cenobamate tablets) CV, an
More news about: SK Life Science, Inc.
Apr 04, 2025, 08:00 ET Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting
pathology, correlating to plasma ptau217 status," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Additionally, our CNS-101 study demonstrated that patients could achieve high levels of adherence performing repeated cognitive and EEG tests at home
More news about: Cumulus Neuroscience
Apr 03, 2025, 11:23 ET Corero Network Security garante um importante contrato de 400G com a TechEnabler, marcando a quarta conquista no Brasil em quatro meses
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), especialista em proteção contra negação de serviço distribuída (DDoS), anunciou uma nova parceria estratégica com a
More news about: Corero Network Security
Apr 03, 2025, 11:18 ET Corero Network Security consigue un importante acuerdo con TechEnabler de 400G, su cuarta victoria en Brasil en cuatro meses
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), especialista en protección contra ataques de denegación de servicio distribuido (DDoS, por sus siglas en inglés), anunció una nueva
More news about: Corero Network Security
Apr 03, 2025, 10:30 ET TRIANGLE INSIGHTS GROUP BY MERCALIS ANNOUNCES PROMOTION OF PARKER GUSE
strong analytical rigor to drive strategic decision-making across client domains. Triangle's expertise encompasses key therapeutic areas (oncology, CNS, and cell and gene therapy) and relevant industry disciplines (pricing and market access, new product planning, and commercial strategy). For more information,
More news about: Mercalis
Apr 03, 2025, 09:00 ET Mitsubishi Tanabe Pharma America to Highlight Latest Advances in Neurodegenerative Research at the American Academy of Neurology 2025 Annual Meeting
combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at
More news about: Mitsubishi Tanabe Pharma America
Apr 03, 2025, 08:00 ET Lindus Health Awarded Funding from ARIA to Build Safe and Reliable AI for Clinical Trial Design
CNS Summit. For more information on ARIA's Safeguarded AI project,
More news about: Lindus Health
Apr 03, 2025, 07:45 ET Capsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson's Disease Associated with GBA Mutations (PD-GBA)
debilitating disease." Presentation Details AD/PD: Title: Systemic AAV Gene Therapy with CNS-Targeted Engineered Capsids Significantly Increases GCase Activity to Support the Potential Treatment of PD-GBADate and Time: Saturday,
More news about: Capsida Biotherapeutics
Apr 03, 2025, 07:35 ET Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting
CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in
More news about: Accuray Incorporated